Merck & Co., Inc.
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, F
·Consolidated from 3 sources
{ "headline": "Agilent PD-L1 Test Gets EU Nod for Ovarian Cancers", "summary": "Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx test has received European Union approval. The diagnostic is now cleared for use in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This development is linked to Merck & Co.'s Keytruda immunotherapy.", "article": "Agilent Technologies has secured European Union approval for
{ "headline": "Agilent PD-L1 Test Gets EU Nod for Ovarian Cancers", "summary": "Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx test has received European Union approval. The diagnostic is now cleared for use in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This development is linked to Merck & Co.'s Keytruda immunotherapy.", "article": "Agilent Technologies has secured European Union approval for
Sources
This recap was generated by consolidating the public headlines below.